



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/055,584	01/23/2002 Michael J. Brubaker		P02975	6941	
7	590 02/23/2005	EXAMINER			
	LOMB INCORPORA	MAIORIN	MAIORINO, ROZ		
One Bausch & Lomb Place Rochester, NY 14604-2701			ART UNIT	PAPER NUMBER	
,		•	3763		

DATE MAILED: 02/23/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

				r- 			
Office Action Summary		Application	n No.	Applicant(s)			
		10/055,584	1 .	BRUBAKER ET AL.			
		Examiner		Art Unit			
		Roz Maiori		3763			
Period fo	The MAILING DATE of this communication apor Reply	ppears on the	cover sheet with the c	orrespondence ad	dress		
THE - Exte after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION nsions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication, period for reply specified above is less than thirty (30) days, a repoperiod for reply is specified above, the maximum statutory perion reto reply within the set or extended period for reply will, by staturely received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	. 1.136(a). In no ever eply within the statut d will apply and will tte, cause the applic	nt, however, may a reply be time ory minimum of thirty (30) days expire SIX (6) MONTHS from tation to become ABANDONE	nely filed s will be considered time! the mailing date of this co D (35 U.S.C. § 133).	y. ommunication.		
Status							
1)[\inf	Responsive to communication(s) filed on 29	November 20	<u>04</u> .				
•		2b) This action is non-final.					
3)□							
Disposit	ion of Claims						
5)□ 6)⊠ 7)□	Claim(s) 1-22 is/are pending in the application. 4a) Of the above claim(s) 3,8-10 and 15-22 is/are withdrawn from consideration. Claim(s) is/are allowed. Claim(s) 1,2,4-7 and 11 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or election requirement.						
Applicat	ion Papers						
10)	The specification is objected to by the Exami The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the corre The oath or declaration is objected to by the	ccepted or b)[ne drawing(s) b ection is require	e held in abeyance. Se ed if the drawing(s) is ob	e 37 CFR 1.85(a). ojected to. See 37 C			
Priority	under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
2) Not 3) Info	nt(s) ice of References Cited (PTO-892) ice of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 er No(s)/Mail Date	08)	4) Interview Summar Paper No(s)/Mail C 5) Notice of Informal 6) Other:	oate	「O-152)		

Application/Control Number: 10/055,584

Art Unit: 3763

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

1. Claims 1-2, 4-7, 11-14 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent NO.5378475 to Smith et al, or US Patent NO. 6001386 to Ashton et al. Both Ashton and Smith teach a sustained drug release agent with a drug core, an impermeable and permeable coating layer and a suture tab adhered to and extending

Application/Control Number: 10/055,584 Page 3

Art Unit: 3763

from the drug delivery device that is used during surgery to adhere said device to the body of a mammalian organism.

2. Claims 1-2, 4-7, 11-14 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent NO.6713081 to Robinson et al or US Patent NO. 6413540 to Yaacobi Or US Patent No. 5902598 to Chen et al.

Chen, Yaccobi and Robinson all teach a sustained drug release agent with a drug core, an impermeable and permeable coating layer and a suture tab adhered to and extending from the drug delivery device that is used during surgery to adhere said device to the body of a mammalian organism.

Response to Arguments

- 3. Applicant's arguments filed 11/29/2004 have been fully considered but they are not persuasive.
 - a. Applicant alleges Smith does not teach an impermeable polymer coating that is adjacent the drug core, or a permeable polymer coating with a suture tab that is made of the same material as the permeable polymer coating, which are cured at the same time. However Smith does teach all of the above limitations. The definition of adjacent is Close to or lying near, and Smith does teach an impermeable layer 10 lying near or close to the drug core 5. Furthermore Smith's permeable member is made out of PVA, which is the same polymer material as the suture tab. (Col.8, line 45-65).

Application/Control Number: 10/055,584

Art Unit: 3763

b. In regards to the curing process argument MPEP 2112.02 states: "[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985)

Page 4

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Roz Maiorino whose telephone number is 571-272-4960. The examiner can normally be reached on 9am-5:30pm.

Application/Control Number: 10/055,584 Page 5

Art Unit: 3763

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nicholas Lucchesi can be reached on 571-272-4377. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

RM

SM